Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic Rx Zegerid deals blow to Santarus

This article was originally published in The Tan Sheet

Executive Summary

The proton pump inhibitor's originator is reducing its workforce by 37 percent, or about 120 employees, and ceasing promotion of Rx Zegerid in light of Prasco Labs' July 1 launch of a generic equivalent. A federal court in April ruled as invalid five patents held by Santarus on Zegerid (omeprazole/sodium bicarbonate), paving the way for generic competition (1"The Tan Sheet" April 19, 2010, In Brief). CEO Gerald Proehl said the layoffs were "an extremely difficult decision" for the San Diego-based firm, which had expected increased prescriptions for Zegerid following Merck/Schering-Plough's April launch of Zegerid OTC (2"The Tan Sheet" Nov. 23, 2009, In Brief). A Santarus spokeswoman said the firm still may receive an additional $37.5 million in Zegerid OTC sales milestones from the licensee

Related Content

Zegerid patents ruled invalid





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts